Together, we can START on a new path to treating Alzheimer’s disease.
Take part in a research study funded by the National Institutes of Health (NIH) that evaluates a new treatment designed to slow the process of memory loss caused by Alzheimer’s disease.
The Synaptic Therapy Alzheimer’s Research Trial (START) is a national study funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH). It is conducted by a network of Alzheimer’s disease experts in collaboration with Cognition Therapeutics.
Through the START Study, we seek to learn if a new treatment, CT1812, can safely slow memory loss caused by Alzherimer’s disease.
Are ages 50 to 85.
Have a diagnosis of either mild cognitive impairment (MCI) due to Alzheimer’s disease or mild Alzheimer’s disease dementia.
Are able and willing to agree to an 18-month commitment in the study.
Are able and willing to take the investigational treatment or placebo daily in the form of oral capsules.
Have a study partner. A study partner is one or more people that have frequent contact with the study participant and agree to take part in information-based assessments in-person and by telephone.
To get STARTed, contact a study location to learn more.
Find a Location
What will participation in this study involve?
Eligibility for the study will be confirmed by study site staff with the use of various medical assessments and procedures. The screening process could take several weeks to complete.
- Take the investigational treatment or placebo capsule(s) once per day, as instructed by study site staff.
- Attend in-person visits for medical assessments and procedures.
- Keep a study partner that helps with giving the investigational treatment to the participant and provides behavior and health information about the participant to study site staff.
A final in-person visit four weeks after the last dose of the study medication and the related study visit.
What is CT1812?
The name of the investigational treatment used in the START Study is CT1812 and it will be taken as an oral capsule. If randomly selected for the placebo, it will also be taken as an oral capsule.
Previous studies have shown that CT1812 has the potential to protect against the memory loss characteristic of Alzheimer’s disease. CT1812 is believed to work by protecting synapses in the brain. Synapses are the points of communication between brain cells and are key to thinking and forming memories.
The investigational treatment is being evaluated for possible benefit in slowing down memory loss caused by Alzheimer’s disease.
Click here to find and contact a study location for more information.
Reasons to Join
Help Determine if CT1812 is an Effective Treatment
Due to an aging population, the number of people with Alzheimer’s disease is expected to soar over upcoming years. Your participation in this research study will help determine if treatment with CT1812 can help slow the process of memory loss caused by Alzheimer’s disease.
Contribute to Groundbreaking Research
Help Your Community and Future Generations
Historically, several communities like the LGBTQ+ community have been underrepresented in research. Others such as the Black/African American, Hispanic/Latinx, Asian American, and Pacific Islander communities are not only underrepresented, but also at higher risk for developing Alzheimer’s disease.
The START Study research team is committed to equity, inclusivity, and diversity. Our commitment extends to seeking participants from every race, ethnicity, gender, sexual orientation, economic background, and geography to discover a treatment that is safe and effective for everyone. Ensure your community is represented by participating or helping a loved one participate in the START Study.
The START Study is funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH) and sponsored by Cognition Therapeutics. The study is being conducted by the NIH-funded Alzheimer’s Clinical Trial Consortium (ACTC), a network of leading academic Alzheimer’s research centers.
The study is led by Alzheimer’s disease research experts and academic leadership at the ACTC, Yale School of Medicine, and Cognition Therapeutics.
The researcher leading the design and implementation of the study is:
Christopher van Dyck, M.D.
Professor of Psychiatry, Neurology, and Neuroscience and Director of the Alzheimer’s Disease Research Unit at the Yale School of Medicine
Co-Chair for the Project Evaluation Committee (PEC) and a member of the Executive Committee for the ACTC